Answers are grounded in this paper and cite their sources.
This study investigates the role of ERK signaling in PS-induced apoptosis and autophagy. PS treatment activated MAP kinases in CTCL cells, with robust ERK activation contrasting with variable p38/JNK responses. Pharmacological ERK inhibition significantly reversed PS-mediated loss of viability, morphological and nuclear alterations, and apoptosis (PI/Annexin V). Mechanistically, ERK blockade suppressed PS-induced cleaved caspase-3, −8, −9, PARP, and γH2AX, confirming ERK drives proapoptotic cascades. PS also triggered autophagic flux, evidenced by increased LC3 and decreased Beclin1/p62, effects reversed by 3-methyladenine. ERK inhibition attenuated PS-induced MDC staining, indicating ERK-dependent autophagic cell death. Moreover, the ROS scavenger N-acetyl-L-cysteine inhibited both PS-induced ERK activation and apoptosis, positioning ROS upstream of ERK signaling. Altogether, these findings demonstrate that PS-mediates ERK-dependent proapoptotic and proautophagic signaling via ROS activity, suggesting ERK signaling as a key determinant of PS’s anticancer activity in CTCL.
No takes yet. Share an insight, caveat, or question.
Anver et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: